Cancer Treatment Today

The PARP inhibitor rucaparib is FDA approved to treat
patients with epithelial ovarian, Fallopian tube, or primary
peritoneal cancer and deleterious somatic or germline
BRCA mutations who have been previously treated with
two or more chemotherapies. Rucaparib is also approved
as a maintenance treatment of patients with recurrent
epithelial ovarian, Fallopian tube, or primary peritoneal
cancer who are in complete or partial response to
platinum-based chemotherapy.
There is some support in the literature for BRCA1 + patientz (Kristeleit et al). However, it is only a single phase I-II study that included lung cancer as “other solid cancers” and mainly focused on ovarian cancer.

There is an ongoing clinical trial: A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II), NCT01482715.

Kristeleit R, Shapiro GI, Burris HA, et al. A phase I-II study of the Oral PARP inhibitor rucaparib in patients with germline BRCA1/2 mutated ovarian carcinoma or other solid tumors. Clin Cancer Res 2017;23:4095106

Kristeleit RS, Shapira-Frommer R, Oaknin A, et al. Clinical activity of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients ( pts) with high-grade ovarian carcinoma (HGOC) and a BRCA mutation (BRCAmut): Analysis of pooled data from Study 10 ( parts 1, 2a, and 3) and ARIEL2 (parts 1 and 2). Presented at: 2016 ESMO Congress; October 7-11, 2016; Copenhagen, Denmark. Abstract 8560.

I. Colombo et al, Moving From Mutation to Actionability. Society of Clinical Oncology Educational Book 38 (May 23, 2018) 495-503.